EDITAS MEDICINE, INC. (EDIT) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -73.95M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-73.95M | (m) |
| 2026-03-31 | (m) | $-108.95M | (m) |
| 2025-12-31 | (m) | $-160.06M | (m) |
| 2025-09-30 | (m) | $-199.84M | (m) |
| 2025-06-30 | (m) | $-236.86M | (m) |
| 2025-03-31 | (m) | $-251.23M | (m) |
| 2024-12-31 | (m) | $-237.09M | (m) |
| 2024-09-30 | (m) | $-210.57M | (m) |
| 2024-06-30 | (m) | $-193.45M | (m) |
| 2024-03-31 | (m) | $-166.13M | (m) |
| 2023-12-31 | (m) | $-153.22M | (m) |
| 2023-09-30 | (m) | $-195.08M | (m) |
| 2023-06-30 | (m) | $-205.79M | (m) |
| 2023-03-31 | (m) | $-218.95M | (m) |
| 2022-12-31 | (m) | $-220.43M | (m) |
| 2022-09-30 | (m) | $-201.13M | (m) |
| 2022-06-30 | (m) | $-184.49M | (m) |
| 2022-03-31 | (m) | $-186.29M | (m) |
| 2021-12-31 | (m) | $-192.50M | (m) |
| 2021-09-30 | (m) | $-213.56M | (m) |
| 2021-06-30 | (m) | $-166.66M | (m) |
| 2021-03-31 | (m) | $-134.98M | (m) |
| 2020-12-31 | (m) | $-115.98M | (m) |
| 2020-09-30 | (m) | $-91.25M | (m) |
| 2020-06-30 | (m) | $-132.01M | (m) |
| 2020-03-31 | (m) | $-142.22M | (m) |
| 2019-12-31 | (m) | $-133.75M | (m) |
| 2019-09-30 | (m) | $-121.03M | (m) |
| 2019-06-30 | (m) | $-103.33M | (m) |
| 2019-03-31 | (m) | $-108.26M | (m) |
| 2018-12-31 | (m) | $-109.95M | (m) |
| 2018-09-30 | (m) | $-121.09M | (m) |
| 2018-06-30 | (m) | $-132.45M | (m) |
| 2018-03-31 | (m) | $-120.17M | (m) |
| 2017-12-31 | (m) | $-120.32M | (m) |
| 2017-09-30 | (m) | $-123.51M | (m) |
| 2017-06-30 | (m) | $-117.93M | (m) |
| 2017-03-31 | (m) | $-110.53M | (m) |
| 2016-12-31 | (m) | $-97.18M | (m) |
| 2016-09-30 | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) |
| 2015-12-31 | (m) | $-72.90M | (m) |
| 2015-09-30 | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) |
| 2014-12-31 | (m) | $-13.69M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |